ATE491044T1 - Gene und polypeptide in verbindung mit brustkrebserkrankungen - Google Patents

Gene und polypeptide in verbindung mit brustkrebserkrankungen

Info

Publication number
ATE491044T1
ATE491044T1 AT05768832T AT05768832T ATE491044T1 AT E491044 T1 ATE491044 T1 AT E491044T1 AT 05768832 T AT05768832 T AT 05768832T AT 05768832 T AT05768832 T AT 05768832T AT E491044 T1 ATE491044 T1 AT E491044T1
Authority
AT
Austria
Prior art keywords
breast cancer
genes
cancer disease
polypeptides linked
polypeptides
Prior art date
Application number
AT05768832T
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of ATE491044T1 publication Critical patent/ATE491044T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT05768832T 2004-08-10 2005-07-29 Gene und polypeptide in verbindung mit brustkrebserkrankungen ATE491044T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60014604P 2004-08-10 2004-08-10
PCT/JP2005/014369 WO2006016525A2 (en) 2004-08-10 2005-07-29 Genes and polypeptides relating to breast cancers

Publications (1)

Publication Number Publication Date
ATE491044T1 true ATE491044T1 (de) 2010-12-15

Family

ID=35063162

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05768832T ATE491044T1 (de) 2004-08-10 2005-07-29 Gene und polypeptide in verbindung mit brustkrebserkrankungen

Country Status (8)

Country Link
US (1) US20090263395A1 (de)
EP (1) EP1786925B1 (de)
JP (1) JP5028601B2 (de)
CN (1) CN101068935B (de)
AT (1) ATE491044T1 (de)
DE (1) DE602005025231D1 (de)
ES (1) ES2357658T3 (de)
WO (1) WO2006016525A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466680B (zh) 2008-08-01 2015-01-01 Oncotherapy Science Inc Ｍｅｌｋ抗原決定位胜肽及含此胜肽的疫苗
TWI485245B (zh) 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
US9120749B2 (en) 2010-07-30 2015-09-01 Oncotherapy Science, Inc. Quinoline derivatives and MELK inhibitors containing the same
AU2012366148B2 (en) 2012-01-19 2016-12-01 Oncotherapy Science, Inc. 1,5-naphthyridine derivatives and melk inhibitors containing the same
AU2017318907B2 (en) 2016-08-31 2023-07-06 Oncotherapy Science, Inc. Monoclonal antibody against MELK and utilization thereof
NL2020004B1 (en) 2016-12-09 2018-07-02 Ary Flohil Jacob Treatment of diffuse intrinsic pontine glioma
CN108997488B (zh) * 2018-08-14 2021-07-30 湖南师范大学 具有抗乳腺癌活性的间斑寇蛛卵粒蛋白质及其制法与应用
CN109929808B (zh) * 2019-04-02 2020-10-16 中国医学科学院医药生物技术研究所 以line-1 orf1蛋白为靶点的抗癌药物筛选模型及筛选方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100209784B1 (ko) * 1996-10-08 1999-07-15 박원훈 인간 단백질 변이인산화효소 유전자(hpk 38), 그의 염기 서열, 효소 단백질 및 그의 아미노산 서열
JP2003534786A (ja) * 2000-05-31 2003-11-25 カイロン コーポレイション 化学療法および放射線感作物質を用いた腫瘍性疾患を処置するための組成物および方法
US20020156263A1 (en) * 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
US20030157082A1 (en) * 2002-01-31 2003-08-21 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 140, 1470, 1686, 2089, 2427, 3702, 5891, 6428, 7181, 7660, 25641, 69583, 49863, 8897, 1682, 17667, 9235, 3703, 14171, 10359, 1660, 1450, 18894, 2088, 32427, 2160, 9252, 9389, 1642, 85269, 10297, 1584, 9525, 14124, 4469, 8990, 2100, 9288, 64698, 10480,20893, 33230,1586, 9943, 16334, 68862, 9011, 14031, 6178, 21225, 1420, 32236, 2099, 2150, 26583, 2784, 8941, 9811, 27444, 50566 or 66428 molecules
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA3061769C (en) * 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
JP2007502115A (ja) * 2003-08-14 2007-02-08 エクセリクシス， インク． ＲＡＣ経路のモディファイヤーとしてのＭＥＬＫｓおよび使用方法

Also Published As

Publication number Publication date
WO2006016525A2 (en) 2006-02-16
JP2008509652A (ja) 2008-04-03
JP5028601B2 (ja) 2012-09-19
EP1786925B1 (de) 2010-12-08
CN101068935B (zh) 2012-06-27
US20090263395A1 (en) 2009-10-22
EP1786925A2 (de) 2007-05-23
CN101068935A (zh) 2007-11-07
ES2357658T3 (es) 2011-04-28
WO2006016525A3 (en) 2006-07-06
DE602005025231D1 (de) 2011-01-20

Similar Documents

Publication Publication Date Title
DK1513934T3 (da) Gener og polypeptider relateret til humane coloncancersygdomme
ATE478094T1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate,die diese enthalten
EA200601946A2 (ru) Антитела, связывающиеся с белками steap-1, и их производные
DE60208397D1 (de) Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung
EP4378962A3 (de) Antikrebsfusionspolypeptid
EP3064509A3 (de) Anti-angiogenese-therapie für die behandlung von ovarialkarzinom
MXPA05012723A (es) Tratamiento con anticuerpos anti-vgf.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
UA116665C2 (uk) Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15)
Yang et al. Roles of protein disulfide isomerase in breast cancer
BR112012013717A2 (pt) "anticorpo de ligação ao csf-1r humano, composição farmacêutica, ácido nuleico, vetor de expressão, célula hospedeira procariótica ou eucariótica , método para a produção de um anticorpo recombinate, uso do anticorpo emétodo para o tratamento de um paciente qur sofre de câncer, de metástase e de doenças inflamatórias"
WO2008093165A3 (en) The use of pgil ohgosaccharyltransferase for o-glycosylating proteins
EP2285989A4 (de) Neue zielmoleküle zur regulierung von angionese
EP2175879A4 (de) Behandlung von erkrankungen im zusammenhang mit prion-protein
Luo et al. Laser immunotherapy for cutaneous squamous cell carcinoma with optimal thermal effects to enhance tumour immunogenicity
Dittz et al. Antiangiogenesis, loss of cell adhesion and apoptosis are involved in the antitumoral activity of Proteases from V. cundinamarcensis (C. candamarcensis) in murine melanoma B16F1
Brnić et al. Treatment strategies for cutaneous and oral mucosal side effects of oncological treatment in breast cancer: a comprehensive review
EP4371610A3 (de) Topische behandlung von entzündlicher darmerkrankung unter verwendung von antikörpern und fragmenten davon
DE602005025231D1 (de) Gene und polypeptide in verbindung mit brustkrebserkrankungen
WO2007015935A8 (en) Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
Mazzotta et al. Role of chemotherapy in vulvar cancers: time to rethink standard of care?
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
ES2186576A1 (es) Acido 2-hidroxioleico para utilizar como medicamento.
MX2008011473A (es) El uso de la nicotina, sus analogos, sus precursores o sus derivados en el tratamiento de diversos procesos patologicos susceptible de mejorar con (-msh administrada en forma profilactica o terapeutica.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties